Bile duct cancer, also known as cholangiocarcinoma, is a malignant tumor that can originate in any part of the bile duct system. Bile duct cancer is considered to be rare as compared to other types of cancer, with less than 8,000 people diagnosed with it every year. Females are less likely to suffer from the disease than males. Nevertheless, survival rates are quite low, starting from around 20% for stage 1 and dropping to 2-3% for stage 4 bile duct cancer. This demonstrates the low efficacy of current diagnostic and treatment protocols.
Depending on where the initial tumor is located, bile duct cancer can be intrahepatic, meaning it is in the small bile ducts of the liver, or extrahepatic, meaning it is perihilar cancer, Klatskin tumors, or distal duct cancer. Based on this classification, the manifestation and treatment of bile duct cancer may differ slightly. Due to the late detection of bile duct cancer and its typically poor prognosis in advanced stages, there is an urgent need for novel therapies, which has led to the discovery of innovative treatment modalities.
π Voiced by AI
π© Please send your request using the following link: https://bit.ly/463WcEc
Β
π You can find more information on our website bookinghealth.com and in our social networks:
Β
YouTube: https://www.youtube.com/@bookinghealth
Facebook: https://www.facebook.com/bookinghealthcom/
Instagram: https://www.instagram.com/bookinghealth_com/
LinkendIn: https://www.linkedin.com/company/bookinghealth/
Twitter: https://twitter.com/booking_health
TikTok: https://www.tiktok.com/@bookinghealth
Β
β You can find more reviews about our company on our website: https://bit.ly/3XcIB9I
Β
#BookingHealth
#askthedoctor
#Treatment
#Bileductcancer
#cancer
Β